News | May 13, 2026
Shilpa Medicare signs long-term CDMO manufacturing deal with NXI Therapeutics
The partnership covers the entire product lifecycle from early-stage development through commercialization
The partnership covers the entire product lifecycle from early-stage development through commercialization
Expands manufacturing push & locks in major growth deals
The deal positions MilliporeSigma at the center of commercial manufacturing for three breakthrough gene therapies targeting sickle cell disease, ?-thalassemia, and cerebral adrenoleukodystrophy
The acquisition brings three established small-molecule drug substance facilities into Siegfried’s global network
Our company is prioritising deeper collaborations with CDMOs and biosimilar companies as part of its strategy to expand its footprint across India, Middle East, and Africa region
Bulling brings extensive experience across the biopharma and CDMO landscape, with leadership roles spanning both drug substance and drug product operations
Collaboration integrates AJICAP™ technology with global manufacturing capabilities to streamline antibody-drug conjugate pipelines
Discussions will focus on how private space stations can improve access, repeatability and commercial feasibility for advanced biotech experiments
The event marks a significant push into South Korea’s rapidly expanding bio-health ecosystem
Ac-225, an alpha-emitting radionuclide, can be paired with molecules designed to selectively target cancer cells.
Subscribe To Our Newsletter & Stay Updated
